Research progress in the effect of combination immunotherapy on myeloid-derived suppressor cells
10.3760/cma.j.cn112309-20231102-00121
- VernacularTitle:免疫联合治疗对髓源性抑制细胞作用的研究进展
- Author:
Fan LEI
1
;
Zhao CUI
;
Yahan QIN
;
Ke ZHANG
;
Meiyu PENG
Author Information
1. 山东第二医科大学免疫微环境与炎症性疾病研究特色实验室，潍坊 261053
- Keywords:
Tumor;
Combined immunotherapy;
Myeloid-derived suppressor cells
- From:
Chinese Journal of Microbiology and Immunology
2024;44(11):992-998
- CountryChina
- Language:Chinese
-
Abstract:
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population of myeloid origin with immunosuppressive function. MDSCs can inhibit the normal immune response of the host to tumor by inhibiting the activity of T cells, natural killer cells, macrophage, B cells, and promoting the proliferation of Treg and other mechanisms. Therefore, MDSCs are potential targets for tumor immunotherapy. However, whether immunotherapy or other treatments, the effectiveness of monotherapy is limited, so immunotherapy combined with other treatments is a breakthrough combination. In recent years, immunotherapy combined with other treatments has shown initial results, with better results than monotherapy. It has become a research hotspot in tumor treatment and a new treatment method in the future. This article summarized the research progress on the effects of immunotherapy combined with chemotherapy, radiotherapy, Chinese herbal extract and Immunotherapy combination on MDSCs, in order to provide theoretical support for the clinical application of immunotherapy based combined tumor treatment measures.
